

01-09-03

BOX 5FQ
H8 03COPlease place a plus sign inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/075,335	
	Filing Date	February 14, 2002	
	First Named Inventor	Stephen D. Ginsberg	
	Group Art Unit	N/A	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	14	Attorney Docket Number	HO-P02202US2

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Sequence Listing - Paper Copy (4 pages)
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Sequence Listing - (CRF) diskette
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	Copy of Noticed 12/5/02
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	Statement - Sequence (2 pages)
<input checked="" type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		Postcard

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual Name	FULBRIGHT & JAWORSKI L.L.P. Melissa L. Sistrunk
Signature	
Date	January 8, 2003

Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU098496255US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: January 8, 2003

Signature: (Monica L. Thomas)


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU098496255US, in an envelope addressed to: Box Sequence, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: January 8, 2003

Signature:

Monica L. Thomas
(Monica L. Thomas)

Docket No.: HO-P02202US2
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Stephen D. Ginsberg, et al.

Application No.: 10/075,335

Group Art Unit: N/A

Filed: February 14, 2002

Examiner: Not Yet Assigned

For: METHODS AND COMPOSITIONS OF
AMPLIFYING RNA

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Box Sequence

Commissioner for Patents
Washington, DC 20231

Dear Sir:

This is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated December 5, 2002. Applicants are submitting their response herewith within the two-month response period set to expire on February 5, 2003.

The U.S. Patent and Trademark Office has taken the position that the previous "Sequence Listing" in computer readable form did not comply with the requirements of Section 1.824 for the stated reason that it contained several raw sequence listing errors. Submitted herewith in connection with the above-referenced patent application is a substitute, computer readable copy of the Sequence Listing that corrects the defects noted in the raw sequence listing. No new matter has been added to the substitute Sequence Listing.


Applicants respectfully request the above-referenced patent application be placed upon the files for examination.

Applicant believes no fee is due with this response. However, if a fee is due, please

charge our Deposit Account No. 06-2375, under Order No. HO-P02202US2 from which the undersigned is authorized to draw.

Dated: January 8, 2003

Respectfully submitted,

By 
Melissa L. Sistrunk
Registration No.: 45,579
FULBRIGHT & JAWORSKI L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-5151
(713) 651-5246 (Fax)
Attorneys for Applicant

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU098496255US, in an envelope addressed to: Box Sequence, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: January 8, 2003

Signature:

(Monica L. Thomas)

Docket No.: HO-P02202US2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Stephen D. Ginsberg, et al.

Application No.: 10/075,335

Group Art Unit: N/A

Filed: February 14, 2002

Examiner: Not Yet Assigned

For: METHODS AND COMPOSITIONS OF
AMPLIFYING RNA

STATEMENT PURSUANT TO 37 CFR 1.823(b))

Box Sequence

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Submitted herewith for filing in connection with the above-referenced patent application is a labeled, computer readable copy of the Sequence Listing included in the application.

I hereby state that I have reviewed the paper copy of the Sequence Listing enclosed herewith for the above-referenced patent application, as required by 37 CFR 1.821(e), and the computer readable form of the Sequence Listing, as required by 37 CFR 1.821(c), and that the content of the paper and computer readable copies are the same. No new matter is entered herein.

Early favorable consideration of the patent application is respectfully solicited.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 06-2375, under Order No. HO-P02202US2 from which the undersigned is authorized to draw.

Dated: January 8, 2003

Respectfully submitted,

By 

Melissa L. Sistrunk

Registration No.: 45,579

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Attorneys for Applicant